vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and AMREP CORP. (AXR). Click either name above to swap in a different company.
AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $10.7M, roughly 1.4× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 21.6%, a 1.9% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 93.8%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -13.6%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
ABUS vs AXR — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $14.6M |
| Net Profit | $2.5M | $3.1M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 20.6% |
| Net Margin | 23.5% | 21.6% |
| Revenue YoY | 522.2% | 93.8% |
| Net Profit YoY | 112.7% | 338.9% |
| EPS (diluted) | $0.01 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.6M | ||
| Q4 25 | — | $9.4M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $10.7M | $11.2M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $19.5M |
| Q1 26 | — | $3.1M | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | $2.5M | $3.9M | ||
| Q1 25 | — | $717.0K | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $4.1M |
| Q1 26 | — | 20.6% | ||
| Q4 25 | — | 11.9% | ||
| Q3 25 | — | 34.4% | ||
| Q2 25 | 13.9% | 31.7% | ||
| Q1 25 | — | 5.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 26.1% | ||
| Q2 24 | — | 23.9% |
| Q1 26 | — | 21.6% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | 23.5% | 34.8% | ||
| Q1 25 | — | 9.5% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 21.3% | ||
| Q2 24 | — | 21.2% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.87 | ||
| Q2 25 | $0.01 | $0.73 | ||
| Q1 25 | — | $0.13 | ||
| Q4 24 | — | $0.75 | ||
| Q3 24 | — | $0.76 | ||
| Q2 24 | — | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $50.0M |
| Total DebtLower is stronger | $0 | $21.0K |
| Stockholders' EquityBook value | $83.0M | $139.4M |
| Total Assets | $103.3M | $143.9M |
| Debt / EquityLower = less leverage | 0.00× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | — | $44.6M | ||
| Q3 25 | — | $48.9M | ||
| Q2 25 | $37.4M | $39.5M | ||
| Q1 25 | — | $36.9M | ||
| Q4 24 | — | $40.1M | ||
| Q3 24 | — | $40.4M | ||
| Q2 24 | — | $29.7M |
| Q1 26 | — | $21.0K | ||
| Q4 25 | — | $23.0K | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | $0 | $26.0K | ||
| Q1 25 | — | $29.0K | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | — | $34.0K | ||
| Q2 24 | — | $35.0K |
| Q1 26 | — | $139.4M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | — | $134.7M | ||
| Q2 25 | $83.0M | $130.0M | ||
| Q1 25 | — | $126.0M | ||
| Q4 24 | — | $125.1M | ||
| Q3 24 | — | $122.2M | ||
| Q2 24 | — | $118.0M |
| Q1 26 | — | $143.9M | ||
| Q4 25 | — | $140.1M | ||
| Q3 25 | — | $140.7M | ||
| Q2 25 | $103.3M | $133.8M | ||
| Q1 25 | — | $128.9M | ||
| Q4 24 | — | $129.1M | ||
| Q3 24 | — | $127.0M | ||
| Q2 24 | — | $122.8M |
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | 0.00× | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $5.4M |
| Free Cash FlowOCF − Capex | — | $5.4M |
| FCF MarginFCF / Revenue | — | 37.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -6.24× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | $20.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | $-15.7M | $10.2M | ||
| Q1 25 | — | $-3.2M | ||
| Q4 24 | — | $-182.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $10.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $-3.3M | ||
| Q4 24 | — | $-268.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $10.3M |
| Q1 26 | — | 37.0% | ||
| Q4 25 | — | -45.9% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 86.4% | ||
| Q1 25 | — | -43.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 52.5% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 2.3% |
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | -6.24× | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 2.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
